Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Basem William
Clinical risk factors alone do not predict the development of moderate-severe chronic graft-versus-host disease after hematopoietic cell transplantation and post-transplant cyclophosphamide
Chronic graft-versus-host disease (GVHD) is a leading cause of morbidity and mortality after hematopoietic cell transplantation (HCT) [1]. Clinical risk factors for the development of chronic GVHD are well described, as are strategies that decrease the risk of chronic GVHD, such as post-transplant cyclophosphamide (PTCy) [2].
GDIS-Bio: A Generalized Dynamical Instability Framework for Localizing Transcriptional State Transitions in Single-Cell Trajectories
Submitted: 21 September 2026 Posted: 22 September 2026 You are already at the latest version Background/Objectives: Single-cell RNA sequencing enables reconstruction of developmental trajectories, but identifying regions of major transcriptional state reorganization remains challenging, particularly when no explicit dynamical model is available.
Early Detection of Critical Transcriptomic State Transitions in Cancer Through Nonlinear Dynamical Systems Analysis
You are already at the latest version Understanding critical transcriptomic state transitions is essential for elucidating cancer progression and therapeutic response. Although single-cell transcriptomics has transformed the study of cellular heterogeneity, existing approaches primarily characterize gene expression changes or pseudotemporal ordering rather than the underlying dynamics of cellular state transitions.
Flow cytometry of DNMT1 as a biomarker of hypomethylating therapies
1 INTRODUCTION Cytotoxic chemotherapy for cancer has been continuously developed since 1946 (Einhorn, 1985). The approach has been successful for wild type TP53/INK4A pathway cancers, representing ~20% of all cancers. Cessation of replication via cell cycle exit via terminal-differentiation does not require TP53/INK4A pathways, and therefore, differentiation-restoring therapy is an alternative approach to cytotoxic therapy for cancers (Velcheti et al., 2017).
Age is No Barrier: CAR-T Therapy in Older Adults
Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software
Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial
Summary Background Most patients with advanced-stage indolent non-Hodgkin lymphoma have multiple relapses. We assessed axicabtagene ciloleucel autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory indolent non-Hodgkin lymphoma. Methods ZUMA-5 is a single-arm, multicentre, phase 2 trial being conducted at 15 medical cancer centres in the USA and two medical cancer centres in France.
IPH4102 in relapsed/refractory cutaneous T cell lymphoma (CTCL): Results of the first-in-human multicenter phase 1 study
To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect. Aims: IPH4102 is a first-in-class monoclonal antibody that targets KIR3DL2, which is widely expressed in different CTCL subtypes. Currently, effective treatment options are limited for CTCL patients with relapsed/refractory disease.
Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome
|
Patients and Methods We examined 2,133 patients with MDS undergoing HLA-matched (n = 1,728) or -mismatched (n = 405) allo HCT from 2000 to 2012. We used a Cox multivariable model to identify factors prognostic of mortality in a training subset (n = 1,151) of the HLA-matched cohort. A weighted score using these factors was assigned to the remaining patients undergoing HLA-matched allo HCT (validation cohort; n = 577) as well as to patients undergoing HLA-mismatched allo HCT.
By Michael Grunwald Verified, Aaron Gerds, Richard Olsson, William Wood, Luciano Costa Verified, Alan Miller, Jorge Cortés, Ravi Vij, Uday Popat, Matt Kalaycio, Richard T Maziarz, Steven Z. Pavletic, Kwang Woo Ahn, Zhen-Huan Hu, Taiga Nishihori, Adriana K. Malone, David Valcárcel, Ulrike Bacher, Betty Hamilton, Mohamed A. Kharfan-Dabaja, Ayman Saad, Corey Cutler, Erica Warlick, Ran Reshef, Baldeep Mona Wirk, Mitchell Sabloff, Omotayo Fasan, Andrew Daly, Tamila L. Kindwall-Keller, Rammurti Kamble, David A. Rizzieri, Jean-Yves Cahn, Robert Peter Gale, Basem William, Mark Litzow, Peter H. Wiernik, Jane Liesveld, Bipin N. Savani, Celalettin Ustun, Edward Copelan, Edwin Alyea, Ron Sobecks, Martin Tallman, David Marks
|
Journal of Clinical Oncology
Verified
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Basem
Contact Basem, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack